Table of Contents
<< Previous Issue | Nov 2018 (Vol: 2018, Issue: 11) | Next Issue >> |
- Section: Licensing
-
United Therapeutics Licenses Arena’s Ralinepag for US$800 M Upfront
- Section: Mergers & Acquisitions
-
Boston Scientific Continues M&A Spree with US$4.2 B BTG Deal
- Section: Research & Development
-
Eli Lilly Bets Big on Dicerna’s Gene-Silencing Technology
-
Novartis and Pfizer to Explore NASH Combinations
-
Gilead Boosts Oncology Pipeline with Tango Collaboration
-
Merck & Co. Continues to Look at NK Cell Engager Therapies with Dragonfly Therapeutics Pact
-
Sanofi Collaborates with Denali for its RIPK1 Programme
-
Janssen Adds Yuhan’s Lazertinib to its Oncology Pipeline in a US$1.25 B Deal
-
AstraZeneca Expands Immuno-Oncology Collaboration with Innate Pharma
-
LEO Pharma Enters into Rare Skin Diseases with US$760 M Deal with PellePharm